Key Facts updated Jan 2016
OPDIVO®, $3.8 billion
ELIQUIS®, $3.3 billion
ORENCIA®, $2.3 billion
SPRYCEL®, $1.8 billion
Hepatitis C franchise, $1.6 billion
BARACLUDE®, $1.2 billion
YERVOY®, $1.1 billion
SUSTIVA® franchise, $1.1 billion
REYATAZ® franchise, $912 million
Please click on the product links to see the Full Prescribing Information for BARACLUDE®, DAKLINZA™,ELIQUIS®, EMPLICITI™, OPDIVO®, ORENCIA®, REYATAZ®, SPRYCEL®, SUSTIVA®, and YERVOY®, including Boxed WARNINGS for BARACLUDE®, ELIQUIS®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.
Bristol-Myers Squibb Corporate B-roll
This B-roll includes a collection of footage of Bristol-Myers Squibb's campus, corporate signage, research and development, and manufacturing facilities.
Usage Rights & Restrictions
This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.